Insights Archive
Filter by:
April 25, 2025
Plan design development to achieve results.
A well-aligned plan isn’t just cost-effective; it’s built with purpose, supporting your broader healthcare objectives and ensuring long-term impact.
April 25, 2025
6 Ways ClearScript Supports You and Your Members During Open Enrollment—and Beyond
Open enrollment can be a hectic season for HR teams and a confusing time for employees. But it’s also a…
February 6, 2025
Drug Spotlight: Suzetrigine
suzetrigine (VX-548) Manufacturer: Vertex Approval Date: 1/30/2025 Suzetrigine possesses a novel mechanism of action as a voltage-gated sodium channel inactivator…
February 6, 2025
20 Years Strong: Celebrating ClearScript’s Legacy of Stewardship to Our Clients
This year marks a significant milestone for ClearScript: 20 years of trusted stewardship in pharmacy benefits. For two decades, we…
February 6, 2025
Better Information at the Point of Care Saves Time and Money for Members, Prescribers, and Clients
In today’s fast-paced healthcare environment, prescribing medications can be challenging for both prescribers and patients. Determining drug coverage, understanding formulary…
November 4, 2024
ClearScript’s Member Portal and Mobile App: Engaging Members, Managing Costs
At ClearScript, we’re committed to simplifying prescription drug benefits with user-friendly digital tools and resources to help members stay informed and engaged with their healthcare.
July 15, 2024
ClearScript Solutions: MedEmpower™ Fuel
To help plans manage the rising cost of diabetes and weight management while improving member health, ClearScript offers our MedEmpower Fuel™ program.
July 15, 2024
ClearScript: Innovating Transparency from the Start
ClearScript was an early pioneer of transparency in pharmacy benefit management. Unlike the Big Three PBMs, we put patients before profits.
April 3, 2024
Rezdiffra (resmetirom)
On March 14, 2024, drug manufacturer Madrigal Pharmaceuticals announced the approval of Rezdiffra™, a new, first in class oral therapy for nonalcoholic steatohepatitis (NASH). This disease, which impacts an estimated 6-8 million people in the U.S., is underdiagnosed and if left untreated, it can cause serious liver complications. Read more about this approval and its implications.